loading page

Repurposing of FDA-approved Drugs against Active Site and Potential Allosteric Drug Binding Sites of COVID-19 Main Protease
  • +3
  • Merve Yuce,
  • Erdem Cicek,
  • Tuğçe İnan,
  • Aslıhan Başak Dağ,
  • Özge Kürkçüoğlu,
  • Fethiye Aylin Sungur
Merve Yuce
Istanbul Technical University

Corresponding Author:[email protected]

Author Profile
Erdem Cicek
Istanbul Technical University
Author Profile
Tuğçe İnan
Istanbul Technical University
Author Profile
Aslıhan Başak Dağ
Istanbul Technical University Faculty of Science and Letters
Author Profile
Özge Kürkçüoğlu
Istanbul Technical University
Author Profile
Fethiye Aylin Sungur
Istanbul Technical University
Author Profile


The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still has serious negative effects on health, social life, and economics. Recently, vaccines from various companies have been urgently approved to control SARS-CoV-2 infections. However, any specific antiviral drug has not been confirmed so far for regular treatment. An important target is the main protease (Mpro), which plays a major role in replication of the virus. In this study, Gaussian and residue network models are employed to reveal two distinct potential allosteric sites on Mpro that can be evaluated as drug targets besides the active site. Then, FDA-approved drugs are docked to three distinct sites with flexible docking using AutoDock Vina to identify potential drug candidates. 14 best molecule hits for the active site of Mpro are determined. 6 of these also exhibit high docking scores for the potential allosteric regions. Full-atom molecular dynamics simulations with MM-GBSA method indicate that compounds docked to active and potential allosteric sites form stable interactions with high binding free energy (∆Gbind) values. ∆Gbind values reach -52.06 kcal/mol for the active site, -51.08 kcal/mol for the potential allosteric site 1, and -42.93 kcal/mol for the potential allosteric site 2. Energy decomposition calculations per residue elucidate key binding residues stabilizing the ligands that can further serve to design pharmacophores. This systematic and efficient computational analysis successfully determines ivermectine, diosmin and selinexor currently subjected to clinical trials, and further proposes bromocriptine, elbasvir as Mpro inhibitor candidates to be evaluated against SARS-CoV-2 infection
05 Apr 2021Submitted to PROTEINS: Structure, Function, and Bioinformatics
07 Apr 2021Submission Checks Completed
07 Apr 2021Assigned to Editor
14 Apr 2021Reviewer(s) Assigned
07 May 2021Review(s) Completed, Editorial Evaluation Pending
07 May 2021Editorial Decision: Revise Minor
02 Jun 20211st Revision Received
03 Jun 2021Submission Checks Completed
03 Jun 2021Assigned to Editor
05 Jun 2021Review(s) Completed, Editorial Evaluation Pending
06 Jun 2021Editorial Decision: Accept